| Name | Title | Contact Details |
|---|
Complex contract disputes. Insurance claims. Project difficulties. Litigation. These and other challenges can keep businesses from achieving their target financial results, delay recovery after disruption, and even deprive them of future growth opportunities. Imperium Consulting Group employs a team of experts across multiple professional disciplines to help clients measure and mitigate the economic impact of claims, from property loss to contract disputes. We develop strategies to improve our clients` capacity to undertake projects, recover from economic loss, protect invested capital, and keep growing. Our approach to client service is based on transparency. We help clients clearly define the goals of every consulting engagement and then explain the steps we`ll take to help our clients reach those objectives. We recognize claims come with inherent uncertainty regarding the outcome. We employ highly competent practitioners that not only understand how to assess financial impacts but also navigate the complexity of different claims processes. For our clients engaging us to assist with project audits and risk assessments, we customize industry best practices to address the specific needs of an assignment. In short, we employ industry specialization, proven methodologies, and a dedication to client service that drive positive outcomes. Imperium`s services include but are not limited to property damage / business interruption claim preparation, insurance loss project management, construction and capital project claims and advisory, and dispute resolution and litigation.
Volo Holdings Fort Pierce is a Fort Pierce, FL-based company in the Business Services sector.
The Glazier Group is a New York, NY-based company in the Business Services sector.
ScoutRock is a Bethesda, MD-based company in the Business Services sector.
Alkeus Pharmaceuticals, Inc. is a late-stage biopharmaceutical company developing transformative therapeutics to address serious, progressive eye diseases that lead to blindness. Our lead compound, ALK-001, is an oral investigational drug being developed for the treatment of Stargardt disease (STGD) and Geographic Atrophy (GA) secondary to dry age-related macular degeneration. ALK-001 is a selectively-deuterated form of Vitamin A that slows the dimerization of Vitamin A, which is implicated in STGD, and has shown statistically-significant and clinically-meaningful efficacy in the TEASE-1 Phase 2 clinical trial. Based on these results, ALK-001 has been granted Breakthrough Therapy Designation for the treatment of Stargardt Disease.